Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jan;71(1):196–200. doi: 10.1038/bjc.1995.40

Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer.

V Ravery 1, M Colombel 1, Z Popov 1, S Bastuji 1, J J Patard 1, J Bellot 1, C C Abbou 1, Y Fradet 1, D K Chopin 1
PMCID: PMC2033441  PMID: 7819039

Abstract

Tumour-associated markers defined by monoclonal antibodies have proven useful to phenotype bladder tumours. In order to evaluate the prognostic value of such markers, we performed an immunohistochemical study on 57 transitional cell carcinomas (23 infiltrative and 34 superficial tumours) and ten healthy bladders using monoclonal antibodies against the external domain of the epidermal growth factor receptor (EGFR) and against the tumour-associated antigens T43, 19A211 and T138. Immunohistochemistry was performed on frozen sections using a two-step alkaline phosphatase method. The staining pattern obtained with each antibody was analysed according to the TNM classification, and results were analysed according to the subsequent clinical course. 19A211 preferentially stained superficial tumours, and T43, T138 and EGFR preferentially stained invasive tumours. Three monoclonal antibodies appeared to have prognostic value, since progression rate survival was significantly (log-rank test) associated with their expression of EGFR (P = 0.017), T138 (P = 0.0009) and T43 (P = 0.031). T138 expression was found to have an independent significant prognostic value using a stepwise logistic regression. T138 antibody may add significant information to classical pathological parameters.

Full text

PDF
196

Images in this article

197Figure 1
on p.197
197Figure 2
on p.197
197Figure 3
on p.197
197Figure 4
on p.197
197Figure 5
on p.197
198Figure 6
on p.198
198Figure 7
on p.198
198Figure 8
on p.198

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berger M. S., Greenfield C., Gullick W. J., Haley J., Downward J., Neal D. E., Harris A. L., Waterfield M. D. Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer. 1987 Nov;56(5):533–537. doi: 10.1038/bjc.1987.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. COHEN S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. 1962 May;237:1555–1562. [PubMed] [Google Scholar]
  3. Dolbeare F., Gratzner H., Pallavicini M. G., Gray J. W. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci U S A. 1983 Sep;80(18):5573–5577. doi: 10.1073/pnas.80.18.5573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fradet Y. Biological markers of prognosis in invasive bladder cancer. Semin Oncol. 1990 Oct;17(5):533–543. [PubMed] [Google Scholar]
  5. Fradet Y., Islam N., Boucher L., Parent-Vaugeois C., Tardif M. Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7227–7231. doi: 10.1073/pnas.84.20.7227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fradet Y., Tardif M., Bourget L., Robert J. Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Laval University Urology Group. Cancer Res. 1990 Jan 15;50(2):432–437. [PubMed] [Google Scholar]
  7. Gates R. E., King L. E., Jr Different forms of the epidermal growth factor receptor kinase have different autophosphorylation sites. Biochemistry. 1985 Sep 10;24(19):5209–5215. doi: 10.1021/bi00340a038. [DOI] [PubMed] [Google Scholar]
  8. Messing E. M. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res. 1990 Apr 15;50(8):2530–2537. [PubMed] [Google Scholar]
  9. Messing E. M., Hanson P., Ulrich P., Erturk E. Epidermal growth factor--interactions with normal and malignant urothelium: in vivo and in situ studies. J Urol. 1987 Nov;138(5):1329–1335. doi: 10.1016/s0022-5347(17)43593-2. [DOI] [PubMed] [Google Scholar]
  10. Neal D. E., Marsh C., Bennett M. K., Abel P. D., Hall R. R., Sainsbury J. R., Harris A. L. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1985 Feb 16;1(8425):366–368. doi: 10.1016/s0140-6736(85)91386-8. [DOI] [PubMed] [Google Scholar]
  11. Neal D. E., Sharples L., Smith K., Fennelly J., Hall R. R., Harris A. L. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer. 1990 Apr 1;65(7):1619–1625. doi: 10.1002/1097-0142(19900401)65:7<1619::aid-cncr2820650728>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  12. Tribukait B., Gustafson H., Esposti P. L. The significance of ploidy and proliferation in the clinical and biological evaluation of bladder tumours: a study of 100 untreated cases. Br J Urol. 1982 Apr;54(2):130–135. doi: 10.1111/j.1464-410x.1982.tb13536.x. [DOI] [PubMed] [Google Scholar]
  13. Young D. A., Prout G. R., Jr, Lin C. W. Production and characterization of mouse monoclonal antibodies to human bladder tumor-associated antigens. Cancer Res. 1985 Sep;45(9):4439–4446. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES